HE HERB.CN Herbal Dispatch Inc. Loading... : Investor Sentiment and Bull/Bear Views

Author argues Herbal Dispatch is an undervalued Canadian cannabis e-commerce micro-cap with real revenue, record October 2025 sales of $4.1M, a positive Q4 forecast, and a recent OTCQB upgrade under LUFFF to improve U.S. investor access. The causal mechanism is that sector tailwinds and U.S. policy shifts could re-rate low-cap Canadian cannabis names, while a 298kg export to Germany and Health Canada-licensed subsidiary support growth. The author flags the stock as volatile and high-risk like most penny stocks.

Author claims Herbal Dispatch (CSE: HERB / OTC Pink: LUFFF) at an ~$8–9M market cap can 10x–20x as its international cannabis export business scales. The mechanism is the company's existing exports to 8 countries, 300+ LP supply network, and targets of 100%+ YoY export revenue growth, tripling export volume by 2028, adding 2–3 new countries annually, and reaching 500 kg/month, potentially driving $50M+ run-rate revenue in 12–24 months. Catalysts include Germany marketing in 2026, GMP/EU-GMP investment, new markets such as UK, Switzerland, Costa Rica, and New Zealand, and premium export pricing. The author conditions the upside on executing most of the export plan, implying execution risk.

Herbal Dispatch is positioned for significant revenue growth through its aggressive international export strategy, targeting 100% YoY growth and expansion into new markets like the UK and Switzerland. The company's low market cap relative to its $16.5M annual sales and potential for acquisition by larger cannabis players provides a favorable risk-reward profile. The main risk is the execution of its export roadmap and the ability to maintain high-margin growth in a competitive sector. Reported returns track the underlying asset, not option P&L.